Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82


First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda.

Poon AFY, Ndashimye E, Avino M, Gibson R, Kityo C, Kyeyune F, Nankya I, Quiñones-Mateu ME, Arts EJ; The Ugandan Drug Resistance Study Team.

AIDS Res Ther. 2019 Jan 22;16(1):3. doi: 10.1186/s12981-019-0218-2.


Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.

Silver N, Paynter M, McAllister G, Atchley M, Sayir C, Short J, Winner D, Alouani DJ, Sharkey FH, Bergefall K, Templeton K, Carrington D, Quiñones-Mateu ME.

AIDS Res Ther. 2018 Nov 8;15(1):18. doi: 10.1186/s12981-018-0206-y.


HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic.

Yendewa GA, Poveda E, Yendewa SA, Sahr F, Quiñones-Mateu ME, Salata RA.

AIDS Rev. 2018 Apr-Jun;20(2):104-113. Review.


Tapering Courses of Oral Vancomycin Induce Persistent Disruption of the Microbiota That Provide Colonization Resistance to Clostridium difficile and Vancomycin-Resistant Enterococci in Mice.

Tomas ME, Mana TSC, Wilson BM, Nerandzic MM, Joussef-Piña S, Quiñones-Mateu ME, Donskey CJ.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02237-17. doi: 10.1128/AAC.02237-17. Print 2018 May.


Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.

Ndashimye E, Avino M, Kyeyune F, Nankya I, Gibson RM, Nabulime E, Poon AFY, Kityo C, Mugyenyi P, Quiñones-Mateu ME, Arts EJ.

AIDS Res Hum Retroviruses. 2018 May;34(5):404-414. doi: 10.1089/AID.2017.0205. Epub 2018 Feb 26.


Sensitive detection of HIV-1 resistance to Zidovudine and impact on treatment outcomes in low- to middle-income countries.

Gibson RM, Nickel G, Crawford M, Kyeyune F, Venner C, Nankya I, Nabulime E, Ndashimye E, Poon AFY, Salata RA, Kityo C, Mugyenyi P, Quiñones-Mateu ME, Arts EJ.

Infect Dis Poverty. 2017 Dec 4;6(1):163. doi: 10.1186/s40249-017-0377-0.


Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease.

Orrú CD, Yuan J, Appleby BS, Li B, Li Y, Winner D, Wang Z, Zhan YA, Rodgers M, Rarick J, Wyza RE, Joshi T, Wang GX, Cohen ML, Zhang S, Groveman BR, Petersen RB, Ironside JW, Quiñones-Mateu ME, Safar JG, Kong Q, Caughey B, Zou WQ.

Sci Transl Med. 2017 Nov 22;9(417). pii: eaam7785. doi: 10.1126/scitranslmed.aam7785.


HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.

Brenner BG, Ibanescu RI, Oliveira M, Roger M, Hardy I, Routy JP, Kyeyune F, Quiñones-Mateu ME, Wainberg MA; Montreal PHI Cohort Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2171-2183. doi: 10.1093/jac/dkx118.


Impaired human immunodeficiency virus type 1 replicative fitness in atypical viremic non-progressor individuals.

Weber J, Gibson RM, Sácká L, Strunin D, Hodek J, Weberová J, Pávová M, Alouani DJ, Asaad R, Rodriguez B, Lederman MM, Quiñones-Mateu ME.

AIDS Res Ther. 2017 Mar 20;14:15. doi: 10.1186/s12981-017-0144-0. eCollection 2017.


Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.

Aralaguppe SG, Winner D, Singh K, Sarafianos SG, Quiñones-Mateu ME, Sönnerborg A, Neogi U.

J Med Virol. 2017 Jan;89(1):106-111. doi: 10.1002/jmv.24610. Epub 2016 Jul 6.


Novel high throughput pooled shRNA screening identifies NQO1 as a potential drug target for host directed therapy for tuberculosis.

Li Q, Karim AF, Ding X, Das B, Dobrowolski C, Gibson RM, Quiñones-Mateu ME, Karn J, Rojas RE.

Sci Rep. 2016 Jun 14;6:27566. doi: 10.1038/srep27566.


Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.

Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, Ndashimye E, Kityo CM, Salata RA, Mugyenyi P, Arts EJ, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16. Print 2016 Jun.


Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencing.

Virk SM, Gibson RM, Quinones-Mateu ME, Barnholtz-Sloan JS.

PLoS One. 2015 May 7;10(5):e0124178. doi: 10.1371/journal.pone.0124178. eCollection 2015.


Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy.

Gibson RM, Weber J, Winner D, Miller MD, Quiñones-Mateu ME.

PLoS One. 2014 Aug 11;9(8):e104512. doi: 10.1371/journal.pone.0104512. eCollection 2014.


HIV-1 and GBV-C co-infection in Venezuela.

Rodríguez AK, Garzaro DJ, Loureiro CL, Gutiérrez CR, Ameli G, Jaspe RC, Porto L, Monsalve F, Pozada Á, Vázquez L, Quiñones-Mateu ME, Pujol FH, Rangel HR.

J Infect Dev Ctries. 2014 Jul 14;8(7):863-8. doi: 10.3855/jidc.3830.


Deep sequencing: becoming a critical tool in clinical virology.

Quiñones-Mateu ME, Avila S, Reyes-Teran G, Martinez MA.

J Clin Virol. 2014 Sep;61(1):9-19. doi: 10.1016/j.jcv.2014.06.013. Epub 2014 Jun 24. Review.


Next-Generation Sequencing to Help Monitor Patients Infected with HIV: Ready for Clinical Use?

Gibson RM, Schmotzer CL, Quiñones-Mateu ME.

Curr Infect Dis Rep. 2014 Apr;16(4):401. doi: 10.1007/s11908-014-0401-5.


Sensitive deep-sequencing-based HIV-1 genotyping assay to simultaneously determine susceptibility to protease, reverse transcriptase, integrase, and maturation inhibitors, as well as HIV-1 coreceptor tropism.

Gibson RM, Meyer AM, Winner D, Archer J, Feyertag F, Ruiz-Mateos E, Leal M, Robertson DL, Schmotzer CL, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2014;58(4):2167-85. doi: 10.1128/AAC.02710-13. Epub 2014 Jan 27.


Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.

Weber J, Rose JD, Vazquez AC, Winner D, Margot N, McColl DJ, Miller MD, Quiñones-Mateu ME.

PLoS One. 2013 Jun 11;8(6):e65631. doi: 10.1371/journal.pone.0065631. Print 2013.


Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism.

Weber J, Vazquez AC, Winner D, Gibson RM, Rhea AM, Rose JD, Wylie D, Henry K, Wright A, King K, Archer J, Poveda E, Soriano V, Robertson DL, Olivo PD, Arts EJ, Quiñones-Mateu ME.

J Clin Microbiol. 2013 May;51(5):1517-27. doi: 10.1128/JCM.00092-13. Epub 2013 Mar 13.


Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism.

Archer J, Weber J, Henry K, Winner D, Gibson R, Lee L, Paxinos E, Arts EJ, Robertson DL, Mimms L, Quiñones-Mateu ME.

PLoS One. 2012;7(11):e49602. doi: 10.1371/journal.pone.0049602. Epub 2012 Nov 14.


Mucosal transmission of human immunodeficiency virus.

Tebit DM, Ndembi N, Weinberg A, Quiñones-Mateu ME.

Curr HIV Res. 2012 Jan 1;10(1):3-8. Review.


HIV microbicides: where are we now?

Quiñones-Mateu ME, Vanham G.

Curr HIV Res. 2012 Jan 1;10(1):1-2.


Virus-inhibitory peptide: a natural HIV entry inhibitor in search for a formal target in the viral genome.

Quiñones-Mateu ME, Schols D.

AIDS. 2011 Aug 24;25(13):1663-4. doi: 10.1097/QAD.0b013e32834a36ea. No abstract available.


Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.

Weber J, Vazquez AC, Winner D, Rose JD, Wylie D, Rhea AM, Henry K, Pappas J, Wright A, Mohamed N, Gibson R, Rodriguez B, Soriano V, King K, Arts EJ, Olivo PD, Quiñones-Mateu ME.

Antimicrob Agents Chemother. 2011 Aug;55(8):3729-42. doi: 10.1128/AAC.00396-11. Epub 2011 May 31.


Identification of low-molecular weight inhibitors of HIV-1 reverse transcriptase using a cell-based high-throughput screening system.

Jegede O, Khodyakova A, Chernov M, Weber J, Menéndez-Arias L, Gudkov A, Quiñones-Mateu ME.

Antiviral Res. 2011 Aug;91(2):94-8. doi: 10.1016/j.antiviral.2011.05.004. Epub 2011 May 12.


Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Selhorst P, Vazquez AC, Terrazas-Aranda K, Michiels J, Vereecken K, Heyndrickx L, Weber J, Quiñones-Mateu ME, Ariën KK, Vanham G.

Antimicrob Agents Chemother. 2011 Apr;55(4):1403-13. doi: 10.1128/AAC.01426-10. Epub 2011 Jan 31. Erratum in: Antimicrob Agents Chemother. 2011 Jul;55(7):3645.


Novel recombinant virus assay for measuring susceptibility of human immunodeficiency virus type 1 group M subtypes to clinically approved drugs.

Covens K, Dekeersmaeker N, Schrooten Y, Weber J, Schols D, Quiñones-Mateu ME, Vandamme AM, Van Laethem K.

J Clin Microbiol. 2009 Jul;47(7):2232-42. doi: 10.1128/JCM.01739-08. Epub 2009 Apr 29.


Current tests to evaluate HIV-1 coreceptor tropism.

Rose JD, Rhea AM, Weber J, Quiñones-Mateu ME.

Curr Opin HIV AIDS. 2009 Mar;4(2):136-42. doi: 10.1097/COH.0b013e328322f973. Review.


Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individuals.

Zapata W, Rodriguez B, Weber J, Estrada H, Quiñones-Mateu ME, Zimermman PA, Lederman MM, Rugeles MT.

Curr HIV Res. 2008 Nov;6(6):531-8.


Impact on replicative fitness of the G48E substitution in the protease of HIV-1: an in vitro and in silico evaluation.

Zimmer JM, Roman F, Lambert C, Jonckheer A, Vazquez A, Plesséria JM, Servais JY, Covens K, Weber J, Van Laethem K, Schmit JC, Vandamme AM, Quinones-Mateu ME, De Maeyer M.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):255-62. doi: 10.1097/QAI.0b013e318174dca6.


Viral drug resistance and fitness.

Quiñones-Mateu ME, Moore-Dudley DM, Jegede O, Weber J, J Arts E.

Adv Pharmacol. 2008;56:257-96. Review. No abstract available.


The impact of viral and host elements on HIV fitness and disease progression.

Henry KR, Weber J, Quiñones-Mateu ME, Arts EJ.

Curr HIV/AIDS Rep. 2007 Feb;4(1):36-41. Review.


Viral fitness: relation to drug resistance mutations and mechanisms involved: nucleoside reverse transcriptase inhibitor mutations.

Weber J, Henry KR, Arts EJ, Quiñones-Mateu ME.

Curr Opin HIV AIDS. 2007 Mar;2(2):81-7. doi: 10.1097/COH.0b013e328051b4e8.


Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity.

Arts EJ, Quiñones-Mateu ME, Albright JL.

Drug Resist Updat. 1998 Mar;1(1):21-8.


Cystic fibrosis and normal human airway epithelial cell response to influenza a viral infection.

Xu W, Zheng S, Goggans TM, Kiser P, Quinones-Mateu ME, Janocha AJ, Comhair SA, Slee R, Williams BR, Erzurum SC.

J Interferon Cytokine Res. 2006 Sep;26(9):609-27.


HIV type 1 tropism and inhibitors of viral entry: clinical implications.

Weber J, Piontkivska H, Quiñones-Mateu ME.

AIDS Rev. 2006 Apr-Jun;8(2):60-77. Review.


Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness.

Weber J, Weberova J, Carobene M, Mirza M, Martinez-Picado J, Kazanjian P, Quiñones-Mateu ME.

J Virol Methods. 2006 Sep;136(1-2):102-17. Epub 2006 May 11.


Role of human beta-defensins in HIV infection.

Weinberg A, Quiñones-Mateu ME, Lederman MM.

Adv Dent Res. 2006 Apr 1;19(1):42-8. Review.


Virus fitness: concept, quantification, and application to HIV population dynamics.

Quiñones-Mateu ME, Arts EJ.

Curr Top Microbiol Immunol. 2006;299:83-140. Review.


Is HIV-1 evolving to a less virulent (pathogenic) virus?

Quiñones-Mateu ME.

AIDS. 2005 Oct 14;19(15):1689-90. No abstract available.


Methods to determine HIV-1 ex vivo fitness.

Abraha A, Troyer RM, Quiñones-Mateu ME, Arts EJ.

Methods Mol Biol. 2005;304:355-68.


The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates.

Ariën KK, Abraha A, Quiñones-Mateu ME, Kestens L, Vanham G, Arts EJ.

J Virol. 2005 Jul;79(14):8979-90.


Diminished replicative fitness of primary human immunodeficiency virus type 1 isolates harboring the K65R mutation.

Weber J, Chakraborty B, Weberova J, Miller MD, Quiñones-Mateu ME.

J Clin Microbiol. 2005 Mar;43(3):1395-400.


Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus.

Chakraborty B, Valer L, De Mendoza C, Soriano V, Quiñones-Mateu ME.

AIDS Res Hum Retroviruses. 2004 Sep;20(9):1026-31.


Drug resistance, virus fitness and HIV-1 mutagenesis.

Chen R, Quinones-Mateu ME, Mansky LM.

Curr Pharm Des. 2004;10(32):4065-70. Review.


HIV-1 mutagenesis during antiretroviral therapy: implications for successful drug treatment.

Chen R, Quinones-Mateu ME, Mansky LM.

Front Biosci. 2005 Jan 1;10:743-50. Print 2005 Jan 1. Review.


Can HIV-1 superinfection compromise antiretroviral therapy?

Chakraborty B, Kiser P, Rangel HR, Weber J, Mirza M, Marotta ML, Asaad R, Rodriguez B, Valdez H, Lederman MM, Quiñones-Mateu ME.

AIDS. 2004 Jan 2;18(1):132-4. No abstract available.


Fitness variations and their impact on the evolution of antiretroviral drug resistance.

Menéndez-Arias L, Martínez MA, Quiñones-Mateu ME, Martinez-Picado J.

Curr Drug Targets Infect Disord. 2003 Dec;3(4):355-71. Review.


Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication.

Quiñones-Mateu ME, Lederman MM, Feng Z, Chakraborty B, Weber J, Rangel HR, Marotta ML, Mirza M, Jiang B, Kiser P, Medvik K, Sieg SF, Weinberg A.

AIDS. 2003 Nov 7;17(16):F39-48.


Supplemental Content

Loading ...
Support Center